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ABSTRACT 
Aims: The aim of the study was to examine prescribing professional's perceptions on prescribed and OTC 
medicines, containing codeine in the Republic of Ireland.  A secondary aim was to examine perceptions on 
codeine dependence, screening and treatment. 
Methods: A cross sectional study of a nationally representative group of prescribing professionals was 
conducted using a questionnaire containing a number of open and closed ended items. Data were analysed using 
SPSS version 21 and content analysis techniques.  
Results: 398 medical professionals participated in the study giving a response rate of 18%. 77% of respondents 
agreed to routinely review patient prescribed codeine. 59% of respondents routinely asked patients about their 
use of OTC medicines and 50% documented use of OTC codeine in their patients' medical notes. 93% indicated 
concern about the potential to purchase codeine from multiple sources. 88% implied that patients did not fully 
understand the risks of taking OTC medicine containing codeine. Only 21% of respondents were confident in 
identifying codeine dependence without being informed by the patient and 11.4% agreed to having suitable 
screening methods in practice. 76% indicated that they would like more instruction on prescribing addictive 
medicines. 
Conclusion: Policy should examine the need for greater public health awareness on codeine use and should 
examine the role of OTC and internet sales in the development of dependence. Further consideration should be 
given to training and support for those who prescribe addictive medicines in practice. 
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Introduction 
The potential misuse and dependence on medicines containing codeine has become a global public health 
concern (1). Misuse is defined as using the medication outside of normal guidelines, for example to induce 
psychoactive effects or alter effects of other consumed drugs, or where the dosage has been increased or used 
longer than advised without medical supervision (1). Dependence is classified as a psychiatric disorder under 
the ICD-10. Codeine a weak opiate is commonly used in the treatment of mild to moderate pain in adults and 
usually combined with paracetamol, aspirin or ibuprofen to improve analgesic efficacy. The maximum 
recommended dosage of codeine is 240mg daily (2). However, prescribed lower codeine combination strengths 
are unlikely to reach the maximum dose (240mg) due to the ratio of other constituents (paracetamol, ibuprofen 
or aspirin) contained in combined formulations. The literature suggests that prolonged use, excessive use and 
misuse of  combination products containing codeine have resulted in significant health problems, including 
gastrointestinal haemorrhage, nephro-toxicity, hypokalaemia and acute haemorrhagic necrotising pancreatitis 
attributed to the combined drug component (3-6). Psychiatric disorders, falls in older people, and medication 
overuse headache have also been reported with continued codeine use (7-10). 
 One factor adding to the codeine debate relates to its availability as an ‘over the counter’ (OTC) drug 
for sale in pharmacies and on the Internet. In 2010, tighter restrictions on the sale of OTC medicines containing 
codeine were placed on pharmacies in the Republic of Ireland.  The restrictions focused on safe supply of 
codeine containing medicines and restricted  the quantity of drug for sale in a single transaction, it removed its 
availability for self-selection and incurred a ban on direct advisement (11). In addition, online pharmacies must 
comply with EU regulations and must carry a logo to inform consumers of their legitimacy as a safe supplier. 
While measures have be taken to reduce the risks associated with codeine consumption, displacement between 
prescribed and OTC availability and the ability to obtain codeine from multiple sources remains a problem (12). 
Consumers are reported to have misconceptions surrounding the safety of OTC medicines and a tendency to 
exchange them freely with friends or relatives (13). Use of codeine amongst recreational and problematic drug 
users is also evident with descriptions of consumption of high doses by extracting codeine from typical codeine 
combination formulations through a process known as ‘cold water extraction’(14, 15). 
There is limited data on current prevalence rates of codeine use, misuse and dependence in Ireland (16) 
and limited information on perspectives of practitioners who prescribe codeine or treat those who become 
dependent on the drug. Equally, there is limited information on screening methods used in detection of codeine 
misuse or treatment options for patients who encounter problems. Some evidence suggests that general 
practitioners (GPs) remain unaware of patients’ OTC medicine use (17), and have limited resources available to 
them when issues of misuse arise. 
The aim of the study was to examine medical professional’s perspectives on prescribed and OTC 
codeine, codeine dependence, screening and treatment options in Ireland.  This study was conducted as part of a 
European Union (EU) research project (www.codemisused.org) that investigated prescribed, OTC and web 
retailed codeine use, misuse and dependence in Ireland, United Kingdom and South Africa. Data for other 
countries is reported separately.  
 
Methods 
 
A cross-sectional postal survey of a representative sample of GPs in Ireland in 2014 was conducted. 
Contact details for GPs were obtained from the Irish Medical Directory. This directory lists all current practicing 
GPs in Ireland (2,552 at the time of survey) stratified by region. A sample size calculation indicated that to 
achieve an 80% power to detect a 50% difference in response distribution and a significance level of 0.05, 335   
responses would be required. Using the expected response rate of between 25 to 30%, it was estimated that 1000 
participants should be contacted in order for the study to be adequately powered. A random sample calculator 
was used to generate a random numbers list and the corresponding details were extracted from the directory and 
prepared for mailing by two members of the research team. 40 Pain Specialists, representing the total population 
available in this field, were also mailed as described.  To ensure representation from nurse prescribers, 200 
Nurse Prescribers were randomly selected to the study and address labelling and postage was facilitated via the 
Irish Nursing Board.  
 
 
 
 
 
A questionnaire informed by the existing literature was developed to explore items related to 
prescribed and OTC codeine, dependence, screening and treatment. This questionnaire was developed following 
a comprehensive review of the literature and consultation between the research team and medical professionals 
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(18). Answers were predominantly on a 5 point Likert scale, with several options for free text insertion. Eight 
questions were used to determine the demographics of the sample. Minor revisions to the questionnaire were 
made following a pilot survey carried out with 8 GPs practising in Ireland. The questionnaire was posted to 
participants with a covering letter requesting participation, information sheet, and a consent form. A stamped 
addressed return envelope was included. A postcard reminder followed two weeks later. Each participant was 
also given the opportunity to complete the questionnaire online (Bristol online surveys) and a link to facilitate 
this was provided in the covering letter. 220 questionnaires were returned complete, six were completed online 
and a further two from direct contact with GPs at an Irish medical conference, 19 -declined to participate and 
one was returned address unknown.  Due to the low response rate a further 1000 GPs were recruited in order to 
reach the target number of participants. This mailing was conducted as previously described.  This yielded a 
further 170 responses and a further two GPs completed the survey online. In total 398 questionnaires were 
completed.   
 Data were coded and entered into IBM SPSS software version 20. For the purposes of data analysis, 
responses to Likert scales (strongly agree, agree, strongly disagree and disagree) were collapsed into binary 
variables (agree and disagree). Neutral responses were also reported. Exploratory factor analysis was used to 
explore the interrelationship between statements and the possibility of refining items into a number of subscales 
for hypothesis testing. Statements specific to ‘Over the Counter Codeine’ showed similar commonalities in the 
form of levels of concern for OTC codeine use. 17 items in the scale were subjected to principle component 
analysis and scree plots were examined. Those with eigenvalues above 1 were chosen as being of interest and 
examined further. Nine of the 17 items were found to be highly correlated and were subsequently collapsed to 
produce a single dimension “level of concern” by combining the nine statements (see figure 1). Variables were 
recoded and given values (strongly agree=2, agree=1, neutral =0, disagree=-1 and strongly disagree=-2) 
Negative item scores were reversed as appropriate and items combined to produce a scale of +18 to -18. Scores 
approaching +18 were highly indicative of concern regarding OTC codeine and vice versa. One way analysis of 
variance (ANOVA) was preformed to evaluate the effect of gender, age, years of practice, profession and 
specialist training on perceived levels of concern.       
 Data from the open-ended questions were entered into a separate Excel®. This data consisted of 
verbatim quotes. This data were examined and thematic categories were created based on the dominant subjects 
identified in the text. Three researchers independently coded the data and discussion took place to check for 
level of agreement with each of the identified categories. Where discrepancies were noted these were resolved 
through group discussion until consensus was reached. Data were then presented as a percentage of the total 
number of responses in each of the identified thematic categories. Ethical approval was granted by the 
Waterford Institute of Technology Research Ethics Committee.   
 
 
Results  
398 medical prescribers participated in the study giving an overall response rate of 18%. Table 1 show 
the demographic details of those who responded to the questionnaire. 83% were working as general practitioners 
(GPs), 13.6% were independent nurse prescribers. 26.9% had formal training in substance misuse. Table 2 
below shows the results for questions examining medical professionals’ experiences of prescribed codeine. 76% 
agreed to routinely review patient prescribed codeine.  35% believed that patients resented them for asking 
about their use of medicine containing codeine while a similar number disagreed with this statement (39%).  
40% believed that requests for codeine were increasing while 29% disagreed.  There was a high level of 
agreement amongst participants that they would only prescribe codeine following unsuccessful treatment with 
non-opioid analgesics (65%). 74% indicated their preference as ‘agree’ (either strongly agree, agree) and would 
avoid the prescribing of codeine with other drugs producing a depressant effect on the body.    
Results regarding statement items related to OTC codeine are shown in Table 3.  59% of respondents 
routinely asked patients about their use of OTC medicines and 50% agreed that they documented the use of 
OTC codeine in their patients’ medical notes. Concern about the availability of OTC medicines containing 
codeine was indicated by 59% of all those responding.  However concern about the potential to purchase 
codeine from multiple sources was higher at 93%.  Similar levels of agreement (34%) and disagreement (40%) 
were shown for the statement item, ‘Patients are given sufficient information on use of over the counter 
medicines containing codeine’. 62% of respondents failed to indicate agreement or disagreement with the 
statement ‘codeine is easily extracted from compounded formulations’.  88% of respondents implied that 
patients did not fully understand the risks of taking OTC medicine containing codeine and 84% indicated 
agreement that patients’ believed OTC codeine to be safe. 
Results of statement items related to dependence, screening and treatment are depicted in Table 4.  
21% of those responding to the questionnaire were confident in identifying codeine dependence in their patients 
without the patient informing them of an issue. Only 11.4% agreed to have suitable screening methods to detect 
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codeine dependence. 76% of all respondents indicated that they would like more instruction on prescribing 
addictive medicines in practice. 
 Perceived levels of concern surrounding OTC codeine use were examined by collapsing the scores of 9 
statements. Scores of +18 were highly indicative of concern while scores approaching -18 were highly 
indicative of a lack of concern regarding OTC codeine.  The mean score was 8.05 (SD 4.11), implying a 
moderate level of concern amongst professionals related to patients’ codeine use.  A one-way ANOVA revealed 
a non-statistically significant difference (p<0.05) on perceived levels of concern, for gender, age, years of 
practice, profession and specialist training in substance misuse (see Table 5).  
 Figure 2 shows the thematic responses as a total percentage of responses from the three main open 
ended questions. Suspicion of codeine dependence was aroused by patients’ requests for prescriptions and 
requesting codeine specifically by name or brand name. Other triggers included patients complaining of 
unresolved pain and aberrant behaviours such as aggression when refused codeine. Treatment by professionals 
was most likely to include the slow and gradual withdrawal of codeine, restricting prescriptions and using 
education and counselling techniques. Referrals to specialist care were indicated where the person could not be 
managed in primary care and were a complex case.  Additional comments made by the respondents in the open 
text section expressed concern regarding public understanding of safe and compliant medicine use and the 
availability to purchase codeine from multiple sources.     
 
Discussion  
Concern with regard to use of codeine medication is evident in the current study. Questioning and 
documenting the use of OTC codeine containing medicines in patients’ medical notes appears to be lacking and 
may be related to the continuity of GP care in Ireland with options for patients to move freely through practices 
(19).  Documentation and questioning regarding  medicine use in routine consultations are considered of vital 
importance for prescribing professionals as it initiates discussion, helps to counteract any patient misconceptions 
and provides opportunities for intervention (20). Concern about the availability of codeine, ability to purchase 
online and through multiple sources is apparent and cannot be ignored. Irish research has found that problematic 
users of codeine obtained their supply by accessing multiple pharmacies, prescribers and purchasing codeine 
based products abroad (21). Availability and access to medicine is of particular concern if the public do not 
engage with information regarding the associated risks (21). Purchasing medicine online is not only a concern 
for codeine containing medicines but for all medicines and in particular where there is a risk that the medicine 
may not be legitimate (22).  Methods to combat illegal sales of medicines across Europe are principally through 
regulated regulatory logos on websites (23). While this approach helps legitimate consumers to make informed 
decisions it does not prevent sales in the illicit market (24). 
Participants’ responses generally indicated disagreement that patients were provided with sufficient 
information on use of medicine containing codeine. Patients were thought to be unaware of risk of dependence 
and safe use of codeine-containing medicines. This was similar to findings reported by practitioners in the UK 
(25). The indication by prescribing professionals regarding patients’ lack of knowledge surrounding their use of 
codeine medicines is worrying and requires greater exploration.  Future efforts must identify the current level of 
knowledge and understanding of the public when purchasing  codeine products -particularly for self-medication 
purposes or where they receive a regular supply on prescription (26). Codeine containing medicines are required 
to contain a patient information leaflet (PIL) and carry a warning of addiction on the outside of the packaging. 
However, such measures do not provide any guarantee that patients fully understand the associated risks. A 
qualitative study examining the views of patients on the usefulness of patient information leaflets (PIL) and 
information on medicines from their professionals found that they only offered partial information. Patients 
were found to read PILs selectively and were most interested in the side effects; however, the language was 
often considered to be too scientific and required greater simplification (27). There is a level of questioning by 
pharmacy staff to check for the appropriate sale of OTC codeine in pharmacies in Ireland. However, it is 
feasible that patients do not engage with the information provided, find it complex, choose to ignore it, and  
have become normalised to questioning during the transaction (21, 28). How this questioning should precede at 
the point of sale should be examined in closer detail. A qualitative study of pharmacists working in Ireland 
found that refusing codeine usually resulted in the product being bought elsewhere (29). 
The question remains on how best to educate patients and improve literacy on medication use. While 
GPs and pharmacists have their role in patient education, it is unlikely that they can perform this function alone. 
A recent review suggest various levels of health literacy exists across countries and significant improvement is 
needed at government level (30). E and M-health technologies may help to improve patients’ understanding of 
medicines and thus improve medication compliance (31).  However, evidence of use of such technologies in this 
manner - remains conflicted (32, 33).   
 
This study also highlights that - options for screening and identification of patients suspected of 
codeine dependence appear lacking. Routine screening is found to be very effective in early identification of 
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issues related to substance use (34).  Awareness on best practice in managing codeine dependence was only 
indicated by a quarter of the respondents, with professionals’ suggesting that they were most likely to use the 
process of gradual withdrawal of medication.  Future efforts should establish best practice in management and 
treatment of codeine dependence in primary care, community and outpatient settings.   
This is one of the first studies comprehensively examining prescribing professional’s perceptions of 
medicines containing codeine in Ireland. There are limitations to this study as it is cross sectional and therefore 
can only be applied to a specific time period. Although the principals of random sampling were used in 
recruitment some bias may exist and it is possible that those experiencing greater problems with codeine in 
practice were more likely to participate in the study. The response rate was also lower than expected. Therefore, 
some caution should be exercised in generalising these findings.  
The findings of this study show that medical professionals working in Ireland have significant levels of 
concern surrounding the sourcing of codeine from multiple outlets and have reservations regarding public 
understanding on use of medicines containing codeine.  Policy should examine the need for greater public health 
awareness on codeine use and should further examine diversionary patterns in development of dependence 
issues. Further consideration should be given to training and support, including screening tools for those who 
prescribe potentially addictive medicines.   
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Table 1 – Showing Demographics of participants by frequency and percentage and 95% CI  
n=398   
 Frequency 
(n) 
% Respondents 95%CI 
    
Gender     
Male  197 49.5 44.5-54.3 
Female 201 50.5 45.7-55.5 
    
Profession    
General Practitioner 330 82.9 79.2-86.4 
Independent/Supplementary  prescriber 54 13.6 10.3-17.1 
Other 14 3.5 1.3-4.0 
    
County    
Munster 116 30 24.8-34.4 
Leinster excluding Dublin 93 24 19.5-27.6 
Dublin 99 25.1 21.0-29.6 
Ulster 32 8.1 5.3-10.9 
Connacht 55 14 10.9-17.5 
    
Location     
Urban  150 37.9 33.3-42.2 
Rural 87 22.0 18.2-26.3 
Mix of both 159 40.2 35.4-44.9 
    
Specialist training in substance misuse     
Yes 107 26.9 22.6-31.2 
No  291 73.1 68.8-77.4 
    
Age    
Mean (years) 50    
Range  28–74   
    
Years of practice     
Mean (years) 22.78   
Range  1-55    
    
Number of consultations per week 106 (Md100)   
Range  0 -370   
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Table 2 – Showing level of agreement (strongly agree and agree) and disagreement (strongly disagree and disagree) and associated confidence intervals for each of the 
statements related to prescribed codeine medicines 
 
 
 
 
 
 
 
 
 
 
 
 
 Agree Neutral Disagree 
Statement n(%) 95% CI n(%) 95%CI n(%) 95%CI 
I routinely review patients who are prescribed medicines containing codeine  280(77) 72.5-81 37(9) 6.5-12.3 56(14) 10.8-17.6 
I believe that patients resent me asking about their use of medicines 
containing codeine 138 (35) 
30-39.9 
 
105(27) 22.2-31.3 153(39) 33.3-43.9 
I feel awkward about asking patients about their codeine use because they 
will think I am accusing them of having a problem 49(12) 
9.1-15.7 60 (15) 11.9-18.2 286(72) 68.1-76.7 
Patients are aware of adverse health consequence associated with high doses 
of combination  codeine preparations 105(27) 
22.2-30.1 79(20) 16.4-24.0 212(54) 49.0-58.3 
It is unlikely that prescribed medicines containing codeine are used as 
recreational drugs 42(11) 
7.9-13.7 43(11) 8.1-14.2 308(78) 74.6-82.2 
Patients’ requests for prescribed medicines containing codeine is increasing 
151(40) 
34.6-44.3 121(32) 24.5-33.6 112(29) 24.5-33.6 
I would avoid prescribing medicines containing codeine with other drug 
groups that also produce a depressant effect on the central nervous system 290(74) 
69.2-77.9 69(18) 14.2-21.6 34(9) 6.1-11.2 
I would generally prescribe medicines containing codeine following 
unsuccessful treatment with non-opioid analgesics 252(65) 
59.8-69.8 78(20) 16.1-23.8 61(16) 12.3-19.4 
I would generally prescribe codeine linctus following unsuccessful treatment 
of cough with non-codeine containing cough suppressants 126(32) 
27.8-37 68(18) 
 
14.1-21.6 195(50) 45.8-55.3 
Doses of less than 30mg of codeine phosphate (compounded or 
uncompounded) are not very effective for treating mild to moderate pain 64(16) 
12.8-19.7 68(17) 13.3-21.2 265(67) 61.5-71.5 
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N=398 Agree Neutral Disagree 
 n(%) 95%CI n% 95%CI n% 95%CI 
Statement       
I routinely ask patients about their use of over the counter medicines 
 
234(59) 54.1-64.0 69(17) 13.6-21.2 93(24) 19-29 
I document the use of over the counter medicine in a patient's medical notes 
 
198(50) 44.2-55.1 85(22) 17.9-26 113(29) 24.2-33.3 
I am concerned about the availability of over the counter medicines containing codeine in 
pharmacies 
 
236(59) 54.4-64.2 79(20) 16.1-23.7 82(21) 16.9-24.7 
 The availability of medicines containing codeine on the internet is a growing concern for the 
medical profession 
 
279(71) 65.7-74.8 100(25.3) 21.2-29.3 17(4.3) 2.5-6.3 
The potential to buy medicines containing codeine from multiple sources adds significantly to the 
potential for misuse 
 
368(93) 90.2-95.2 20(5) 3.0-7.3 9(2.3) 1.0-3.5 
Patients are given sufficient information on use of over the counter medicines containing codeine 
 
135(34) 29.5-38.5 103(26) 21.9-30.5 159(40) 35-44.6 
Medicines containing codeine should be regulated to a prescription only medicine (POM) 
 
247(62) 56.9-67 75(19) 15.4-23.2 75(19) 15.1-22.7 
Over the counter medicines containing codeine give patients better choice for pain relief 
 
196(50) 44.7-54 93(24) 19.4-27.8 107(27) 23-31.3 
Over the counter mixtures containing codeine gives patients better choice for treating cough 
 
112(28) 23.1-32.7 97(24.4) 20.6-28.6 189(48) 42.7-53.0 
Over the counter medicines containing codeine are more effective than non-opioid analgesics 
such as paracetamol and ibuprofen in treating mild to moderate pain 
 
97(25) 20.4-28.5 75(19) 15.1-23.7 225(57) 51.6-23.7 
The potential for misuse of over the counter medicines containing codeine is minimal 21(5) 3.3-7.9 24(6) 3.8-8.7 347(89) 85.5-92.1 
Over the counter medicines containing codeine have greater potential for inappropriate use 
compared to prescribed medicines containing codeine 
 
244(62) 56.8-67 64(16) 12.4-20.1 86(22) 17.5-25.6 
Codeine is easily extracted from compounded formulations (e.g. Cocodamol) increasing its abuse 
potential 
 
108(28) 23.6-32.1 241(62) 57.4-66.2 41(11) 7.4- 13.8 
It is likely that over the counter codeine medicines could be used as recreational drugs 
 
326(83) 79.1-86.5 45(12) 8.7-14.5 21(5.5) 3.3-7.7 
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Table 3 – Showing the level of agreement (strongly agree and agree) and disagreement (strongly disagree and disagree) and 95% CI intervals for 
statement items related to OTC codeine medicines 
 
  
Codeine misuse is as serious a problem to society as misuse of stronger opioids 
 
209(53) 47.8-58.2 76(19) 15.4-23.0 110(28) 23.5-33.2 
Patients do not fully understand the risk of dependence in taking over the counter medicines 
containing codeine 
 
348(88) 84.4-90.7 24(6) 3.8-8.6 25(6) 4.3-8.6 
Patients believe that over the counter medicines containing codeine are safe 
 
322(84) 79.8-87.4 48(12) 9.1-15.6 17(4) 2.3-6.3 
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Table 4 – Showing level of agreement and disagreement and CI for statements related to dependence, screening and treatment for codeine use 
and misuse 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Agree  Neutral  Disagree  
Statement n (%) 95%CI n(%) 95% CI n(%) 95% CI 
Patients who take their codeine medication as prescribed 
are not at risk of developing a codeine dependence 
55(14) 10.6-17.4 34(9) 6.0-11.3 308(78) 73.6-81.6 
Patients do not fully understand the risk of dependence 
when taking prescribed medicines containing codeine 
326(83) 78.5-86.3 44(11) 8.1-14.9 25(6) 3.8-8.6 
I find it difficult to identify problematic use of medicines 
containing codeine (including OTCs) without the patient 
first telling me 
190(48) 43.5-53.2 99(25) 21.2-29.8 104(27) 24.4-31.3 
I am confident that I can identify codeine dependence in 
my patients 
81(21) 16.7-24.6 140(35) 30.6-40.3 174(44) 39.5-48.9 
Females are at higher risk of developing a codeine 
dependence than their male counterparts 
185(47) 42.1-51.9 164(41) 36.3-45.8 48(12) 9.1-15.4 
Codeine dependence can be managed effectively in general 
practice 
167(43) 38.1-47.7 82(21) 16.7-24.5 145(37) 32.1-41.7 
I have suitable screening methods that I use to identify 
inappropriate use of medicines containing codeine 
45(11) 8.6-14.7 105(27) 22.1-31.0 244(62) 244(62) 
Support services are readily available in my area to help 
those with a codeine dependence problem 
77(19) 15.4-23.4 58(15) 11.1-18.1 262(66) 61.0-70.8 
I am fully aware of best practice in managing codeine 
misuse and dependence 
103(76) 22-30.3 186(47) 41.9-52 107(27) 22.5-31.6 
I would like more instruction on prescribing potentially 
addictive medications 
300(76) 71.9-79.7 59(15) 11.6-18.5 36(9) 6.6-11.9 
 Mean 
(SD) 
Level of Significance 
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 Table 5 – Showing mean scores for scale item ‘level of concern’ regarding codeine 
use and level of significance by variable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gender   
Male 7.9(4.0) F=0.260, DF 1, 
p=0.610 Female 8.4(4.3) 
 
AGE (years)   
Less than 30 9.5 (1.1) F=1.159, DF 4, 
P=0.329 31-40 7.3 (7.3) 
41-50 8.2(3.7) 
51-60 8.2(3.9) 
61 or greater 8.5(4.4) 
 
Profession    
General 
Practitioner 
8.2(4.1) F=1.5, DF 2, P=0.199 
Nurse/independent 
prescriber 
7.0(4.2) 
Other 7.0(3.9) 
 
Years of practice   
0-5 7.3(4.1) F=1.307, DF 3, 
P=0.272 6-10 7.3(4.9) 
11-20 8.4(3.7) 
21 or greater 8.1(4.1) 
   
Specialist 
training in 
substance misuse 
  
Yes 8.0 (3.9) F=0.001, DF 1, P=972 
No 8.05(4.1) 
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Figure 1 – Showing statement items used in generation of scale measuring concern about OTC codeine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statement items  
I am concerned about the availability of over the counter medicines containing codeine in pharmacies  
The availability of medicines containing codeine on the internet is a growing concern for the medical profession 
The potential to buy medicines containing codeine from multiple sources adds significantly to the potential for 
misuse 
Medicines containing codeine should be regulated to a prescription only medicine (POM) 
The potential for misuse of over the counter medicines containing codeine is minimal  
It is likely that over the counter codeine medicines could be used as recreational drugs  
Codeine misuse is as serious a problem to society as misuse of stronger opioids  
Patients do not fully understand the risk of dependence in taking over the counter medicines containing codeine 
Patient believe that over the counter codeine medicines are safe 
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Figure 2 – Frequency of responses displayed as a percentage for each thematic category   
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